New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
16:20 EDTGHDXGenomic Health sees 2H net losses similar to 1H
"Our first half net loss reflects planned investments in the international and prostate cancer markets," said Brad Cole, COO and CFO of Genomic Health. "We anticipate planned investments in DCIS, prostate and international markets to continue through the end of the year, resulting in second half net losses similar to the first half."
News For GHDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 20, 2015
08:04 EDTGHDXGenomic Health reports positive data on positive impact of Oncotype DX test
Genomic Health announced that 11 studies were presented at the 14th St. Gallen International Breast Cancer Conference, including positive results from a real-life observational study in Ireland.1 That study demonstrated that use of the Oncotype DX test in early-stage breast cancer led to a 58 percent net reduction in chemotherapy use, resulting in net cost savings of nearly EUR 800,000, or approximately EUR 1,200 in cost savings per patient.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use